Breaking News

Baxalta Completes Acquisition of ONCASPAR Portfolio

Brings significant growth potential of at least $500 million

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Baxalta Inc. (formerly Baxter BioScience) has completed the acquisition of the ONCASPAR (pegaspargase) portfolio from Sigma-Tau Finanziaria S.p.A, for approximately $900 million. ONCASPAR, for the treatment of acute lymphoblastic leukemia (ALL), is a novel investigational biologic calaspargase pegol, with a established global clinical and commercial resources. ONCASPAR is a biologic cancer therapy used as a component of multi-agent chemotherapeutic regimens to treat acute lymphoblastic leuke...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters